Your Shopping Cart Is Empty
| Report Code: A13121 | Aug 2021 | Pages: 274 | ||
| Tables: 119 | Charts: 55 |
| |
Pandemic disrupted the entire world and affected many industries.
Get detailed COVID-19 impact analysis on the Central Nervous Disorders Therapeutics Market
Request Now !The central nervous disorders therapeutics market generated $1,17,556.10 million in 2020, and is projected to reach $2,32,294.20 million by 2030, growing at a CAGR of 7.3% from 2021 to 2030.
Central nervous system is a part of the nervous system, which controls most functions of the body and mind. It consists of two parts, brain, and spinal cord. It integrates the received information, thereafter, coordinating and controlling activities of all parts of the body. However, central nervous system disorders include neurovascular diseases, degenerative diseases, infectious diseases, mental health, and other diseases, which affect structure and function of brain or spinal cord. Thus, CNS treatment is used to treat these disorders. In addition, the central nervous disorders therapeutics market is anticipated to grow substantially during the forecast period, owing to increase in geriatric population and rise in case of CNS disorders such as neurovascular diseases, degenerative diseases, Alzheimer's disease, Parkinson's disease, multiple sclerosis, infectious diseases, mental health, anxiety disorders, bipolar disorder, and depression.
Moreover, increase in demand for effective CNS treatment and therapeutic options encourages major pharmaceutical companies to invest in R&D, which creates future growth opportunities. Furthermore, rise in R&D activities for introduction of novel drugs and advancements in diagnostics technologies to develop superior drug delivery system are anticipated to propel the market for central nervous system disorder treatment.
In addition, rise in prevalence of CNS disorders and presence of strong pipeline drugs are the major factors that drive growth of the central nervous disorders therapeutics market. However, high treatment cost hampers the market growth, especially high cost of treatment in developing countries. Moreover, introduction of a novel drug delivery systems in CNS and advancements in technologies to develop superior drug delivery systems are expected to create future growth opportunities for the central nervous disorders therapeutics market.
Coronavirus (COVID-19) was discovered in December 2019 in Hubei province of Wuhan city in China. The disease is caused by a virus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is transmitted from humans to humans.
After its discovery in Wuhan, the disease rapidly spread to other parts of the globe. Moreover, this virus causes various symptoms in patients, which range from common symptoms to serious symptoms. For instance, common symptoms include fever, dry cough, and fatigue. However, serious symptoms include difficulty in breathing or shortness of breath, chest pain or pressure, and loss of speech or movement.
Furthermore, the virus has high potential of lethality in geriatric population. On 11th March 2020, the World Health Organization made an assessment that COVID-19 can be characterized as pandemic. In addition, there are only a few vaccines that received emergency approvals for COVID-19 treatment or prevention. Thus, social-distancing is observed as the most important measure to stop the spread of this disease. Furthermore, to maintain social distancing, various countries across the world have adopted nationwide lockdowns. Most markets are experiencing a decline, owing to the outbreak. This also includes the central nervous disorders therapeutics market. In addition, COVID-19 severely affects the respiratory system and it has been reported to show effects on central and peripheral systems. This included encephalopathy, inflammation, ischemic stroke, and peripheral neurological disorders. Moreover, patients suffering from severe illness from COVID-19 have neurologic manifestations of acute cerebrovascular disease, impaired consciousness, and skeletal muscle injury. According to the National Center for Biotechnology Information (NCBI), data published in 2020, states that patients with pneumonia typically develop hypoxic or type 1 respiratory failure, with low CO2 levels and a raised respiratory rate, while brain failure typically leads to type 2 respiratory failure and involves low oxygen, high CO2 and reduced respiratory rate. In addition, COVID-19 may have minimal impact on the central nervous disorders therapeutics market.
The central nervous disorders therapeutics market is classified on the basis of disease, distribution channel, age group, and region. By disease, the market is divided into neurovascular diseases, degenerative diseases (Alzheimer's diseases, Parkinson's disease, multiple sclerosis, and others), infectious diseases, mental health (anxiety disorders, bipolar disorder, depression, and others), and other diseases. By distribution channel, it is categorized into hospital-based pharmacies, retail pharmacies, and online pharmacies. By age group, it is segmented into pediatric, adult, and geriatric. By region, the market is analyzed across, North America, Europe, Asia-Pacific, and LAMEA.
By disease, the degenerative disease segment accounted for the largest share in the central nervous disorders therapeutics market in 2020. In addition, this segment is expected to maintain its position during the forecast period. Key factors, such as increase in geriatric population, which is prone to CNS disorder including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other diseases are set to drive growth of the market.
By distribution channel, the hospital-based pharmacies segment accounted for a major share of the market share in the central nervous disorders therapeutics market in 2020. This segment is expected to exhibit a prominent growth rate, owing to rapid increase of central nervous system disorder rate in geriatric population, technological advancements, and lifestyle change, which augments the market growth.
By age group, the geriatric age group segment contributed for a large share in 2020, which was accounted for three-fifths of the total market share. In addition, this segment is expected to maintain its position during the forecast period.
By region, the market is divided into North America, Europe, Asia-Pacific, and LAMEA. The North America dominated the market for central nervous system disorder treatment and held the largest revenue share in 2020, with highest growth rate majorly due to changing lifestyle conditions, increase in geriatric population, and increase in cases of central nervous system disorder.
Key players operating in the central nervous disorders therapeutics market include Biogen, Otsuka Pharmaceutical Co. Ltd., Eli Lilly and Company, Merck & Co., Astra Zeneca, Shire PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc. and Pfizer, Inc.
Key Benefits For Stakeholders
Key Market Segments
By Disease
By Distribution Channel
By Age Group
By Region
List of key players profiled in the report
Central Nervous Disorders Therapeutics Market Report Highlights
| Aspects | Details |
|---|---|
| By Disease |
|
| By Distribution Channel |
|
| By Age Group |
|
| By Region |
|
| Key Market Players | AstraZeneca PLC., Ostuka Pharmaceuticals Ltd, PFIZER INC., Eli Lily and Company., Merck & Co., Inc., Novartis AG, Shire Plc., Biogen, Inc, Johnson & Johnson, Teva Pharmaceuticals, Inc. |
CHAPTER 1:INTRODUCTION
1.1.Report description
1.2.Key benefits for stakeholders
1.3.Key market segments
1.3.1.List of key players profiled in the report
1.4.Research methodology
1.4.1.Secondary research
1.4.2.Primary research
1.4.3.Analyst tools & models
CHAPTER 2:EXECUTIVE SUMMARY
2.1.Key findings of the study
2.2.CXO perspective
CHAPTER 3:MARKET OVERVIEW
3.1.Market definition and scope
3.2.Key findings
3.2.1.Top investment pockets
3.2.2.Top winning strategies
3.2.3.Top positioning players
3.3.Porter’s five force analysis
3.4.Market dynamics
3.4.1.Drivers
3.4.1.1.Increasing Prevalence of CNS Disorders
3.4.1.2.Presence of Strong Pipeline Drugs
3.4.2.Restraints
3.4.2.1.High treatment cost
3.4.3.Opportunity
3.4.3.1.Introduction of a Novel Drug Delivery Systems in CNS
3.5.COVID-19 impact on the global central nervous system disorder treatment market
CHAPTER 4:CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE
4.1.Overview
4.1.1.Market size and forecast
4.2.Neurovascular Diseases
4.2.1.Key market trends, growth factors, and opportunities
4.2.2.Market size and forecast, by region
4.2.3.Market analysis, by country
4.3.Degenerative Diseases
4.3.1.Key market trends, growth factors, and opportunities
4.3.2.Market size and forecast, by type
4.3.2.1.Alzheimer's Disease
4.3.2.1.1.Market size and forecast
4.3.2.2.Parkinson's Disease
4.3.2.2.1.Market size and forecast
4.3.2.3.Multiple Sclerosis
4.3.2.3.1.Market size and forecast
4.3.2.4.Others
4.3.2.4.1.Market size and forecast
4.3.3.Market size and forecast, by region
4.3.4.Market analysis, by country
4.4.Mental Health
4.4.1.Key market trends, growth factors, and opportunities
4.4.2.Market size and forecast, by type
4.4.2.1.Psychotic disorder
4.4.2.1.1.Market size and forecast
4.4.2.2.Epilepsy
4.4.2.2.1.Market size and forecast
4.4.2.3.Depression
4.4.2.3.1.Market size and forecast
4.4.2.4.Others
4.4.2.4.1.Market size and forecast
4.4.3.Market size and forecast, by region
4.4.4.Market analysis, by country
4.5.Infectious Diseases
4.5.1.Key market trends, growth factors, and opportunities
4.5.2.Market size and forecast, by region
4.5.3.Market analysis, by country
4.6.Others Disease
4.6.1.Key market trends, growth factors, and opportunities
4.6.2.Market size and forecast, by region
4.6.3.Market analysis, by country
CHAPTER 5:CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL
5.1.Overview
5.1.1.Market size and forecast
5.2.Hospital-based pharmacies
5.2.1.Market size and forecast
5.2.2.Market analysis, by country
5.3.Retail pharmacy
5.3.1.Market size and forecast
5.3.2.Market analysis, by country
5.4.Online Pharmacy
5.4.1.Market size and forecast
5.4.2.Market analysis, by country
CHAPTER 6:CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP
6.1.Overview
6.1.1.Market size and forecast
6.2.Pediatric
6.2.1.Market size and forecast, by region
6.2.2.Market analysis, by country
6.3.Adults
6.3.1.Market size and forecast, by region
6.3.2.Market analysis, by country
6.4.Geriatric
6.4.1.Market size and forecast, by region
6.4.2.Market analysis, by country
CHAPTER 7:GLOBAL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY REGION
7.1.Overview
7.1.1.Market size and forecast
7.2.North America
7.2.1.Key market trends, growth factors, and opportunities
7.2.2.Market size and forecast, by country
7.2.2.1.U.S.
7.2.2.1.1.U.S. central nervous disorders therapeutics market, by disease
7.2.2.1.2.Sciential nervous disorders therapeutics market, by distribution channel
7.2.2.1.3.U.S. central nervous disorders therapeutics market, by age group
7.2.2.2.Canada
7.2.2.2.1.Canada central nervous disorders therapeutics market, by disease
7.2.2.2.2.Canada central nervous disorders therapeutics market, by distribution channel
7.2.2.2.3.Canada central nervous disorders therapeutics market, by age group
7.2.2.3.Mexico
7.2.2.3.1.Mexico central nervous disorders therapeutics market, by disease
7.2.2.3.2.Mexico central nervous disorders therapeutics market, by distribution channel
7.2.2.3.3.Mexico central nervous disorders therapeutics market by age group
7.2.3.North America market size and forecast, by disease
7.2.4.North America market size and forecast, by distribution channel
7.2.5.North America market size and forecast, by age group
7.3.Europe
7.3.1.Key market trends, growth factors, and opportunities
7.3.2.Market size and forecast, by country
7.3.2.1.Germany
7.3.2.1.1.Germany central nervous disorders therapeutics market, by disease
7.3.2.1.2.Germany central nervous disorders therapeutics market, by distribution channel
7.3.2.1.3.Germany central nervous disorders therapeutics market, by age group
7.3.2.2.France
7.3.2.2.1.France central nervous disorders therapeutics market, by disease
7.3.2.2.2.France central nervous disorders therapeutics market, by distribution channel
7.3.2.2.3.France central nervous disorders therapeutics market, by age group
7.3.2.3.UK
7.3.2.3.1.UK central nervous disorders therapeutics market, by disease
7.3.2.3.2.UK central nervous disorders therapeutics market, by distribution channel
7.3.2.3.3.UK central nervous disorders therapeutics market, by age group
7.3.2.4.Italy
7.3.2.4.1.Italy central nervous disorders therapeutics market, by disease
7.3.2.4.2.Italy central nervous disorders therapeutics market, by distribution channel
7.3.2.4.3.Italy central nervous disorders therapeutics market, by age group
7.3.2.5.Spain
7.3.2.5.1.Spain central nervous disorders therapeutics market, by disease
7.3.2.5.2.Spain central nervous disorders therapeutics market, by distribution channel
7.3.2.5.3.Spain central nervous disorders therapeutics market, by age group
7.3.2.6.Rest of Europe
7.3.2.6.1.Rest of Europe central nervous disorders therapeutics market, by disease
7.3.2.6.2.Rest of Europe central nervous disorders therapeutics market, by distribution channel
7.3.2.6.3.Rest of Europe central nervous disorders therapeutics market, by age group
7.3.3.Europe market size and forecast, by disease
7.3.4.Europe market size and forecast, by distribution channel
7.3.5.Europe market size and forecast, by age group
7.4.Asia-Pacific
7.4.1.Key market trends, growth factors, and opportunities
7.4.2.Market size and forecast, by country
7.4.2.1.Japan
7.4.2.1.1.Japan central nervous disorders therapeutics market, by disease
7.4.2.1.2.Japan central nervous disorders therapeutics market, by distribution channel
7.4.2.1.3.Japan central nervous disorders therapeutics market, by age group
7.4.2.2.China
7.4.2.2.1.China central nervous disorders therapeutics market , by disease
7.4.2.2.2.China central nervous disorders therapeutics market , by distribution channel
7.4.2.2.3.China central nervous disorders therapeutics market , by age group
7.4.2.3.Australia
7.4.2.3.1.Australia central nervous disorders therapeutics market, by disease
7.4.2.3.2.Australia central nervous disorders therapeutics market, by distribution channel
7.4.2.3.3.Australia central nervous disorders therapeutics market, by age group
7.4.2.4.India
7.4.2.4.1.India central nervous disorders therapeutics market, by disease
7.4.2.4.2.India central nervous disorders therapeutics market, by distribution channel
7.4.2.4.3.India central nervous disorders therapeutics market, by age group
7.4.2.5.South Korea
7.4.2.5.1.South Korea central nervous disorders therapeutics market, by disease
7.4.2.5.2.South Korea central nervous disorders therapeutics market, by distribution channel
7.4.2.5.3.South Korea central nervous disorders therapeutics market, by age group
7.4.2.6.Rest of Asia-Pacific
7.4.2.6.1.Rest of Asia-Pacific central nervous disorders therapeutics market, by disease
7.4.2.6.2.Rest of Asia-Pacific central nervous disorders therapeutics market, by distribution channel
7.4.2.6.3.Rest of Asia-Pacific central nervous disorders therapeutics market, by age group
7.4.3.Asia-Pacific market size and forecast, by disease
7.4.4.Asia-Pacific market size and forecast, by distribution channel
7.4.5.Asia-Pacific market size and forecast, by age group
7.5.LAMEA
7.5.1.Key market trends, growth factors, and opportunities
7.5.2.Market size and forecast, by country
7.5.2.1.Brazil
7.5.2.1.1.Brazil central nervous disorders therapeutics market, by disease
7.5.2.1.2.Brazil central nervous disorders therapeutics market, by distribution channel
7.5.2.1.3.Brazil central nervous disorders therapeutics market, by age group
7.5.2.2.Saudi Arabia
7.5.2.2.1.Saudi Arabia central nervous disorders therapeutics market, by disease
7.5.2.2.2.Saudi Arabia central nervous disorders therapeutics market, by distribution channel
7.5.2.2.3.Saudi Arabia central nervous disorders therapeutics market, by age group
7.5.2.3.South Africa
7.5.2.3.1.South Africa central nervous disorders therapeutics market, by disease
7.5.2.3.2.South Africa central nervous disorders therapeutics market, by distribution channel
7.5.2.3.3.South Africa central nervous disorders therapeutics market, by age group
7.5.2.4.Rest of LAMEA
7.5.2.4.1.Rest of LAMEA central nervous disorders therapeutics market, by disease
7.5.2.4.2.Rest of LAMEA central nervous disorders therapeutics market, by distribution channel
7.5.2.4.3.Rest of LAMEA central nervous disorders therapeutics market, by age group
7.5.3.LAMEA market size and forecast, by disease
7.5.4.LAMEA market size and forecast, by distribution channel
7.5.5.LAMEA market size and forecast, by age group
CHAPTER 8:COMPANY PROFILES
8.1.AstraZeneca PLC.
8.1.1.Company overview
8.1.2.Company snapshot
8.1.3.Operating business segments
8.1.4.Product Portfolio
8.1.5.Business performance
8.2.Biogen, Inc
8.2.1.Company overview
8.2.2.Operating business segments
8.2.3.Product portfolio
8.2.4.Business performance
8.2.5.Key strategic moves and developments
8.3.Eli Lily and Company.
8.3.1.Company overview
8.3.2.Company snapshot
8.3.1.Operating business segments
8.3.2.Product portfolio
8.3.3.Business performance
8.3.4.Key strategic moves and developments
8.4.Johnson & Johnson
8.4.1.Company overview
8.4.2.Company snapshot
8.4.3.Operating business segments
8.4.4.Product portfolio
8.4.5.Business performance
8.5.Merck & Co., Inc.
8.5.1.Company overview
8.5.2.Company snapshot
8.5.3.Operating business segments
8.5.4.Product portfolio
8.5.5.Business performance
8.5.6.Key strategic moves and developments
8.6.Novartis AG
8.6.1.Company overview
8.6.2.Company snapshot
8.6.3.Operating business segments
8.6.4.Product portfolio
8.6.5.Business performance
8.6.6.Key strategic moves and developments
8.7.Ostuka Pharmaceuticals Ltd
8.7.1.Company overview
8.7.2.Company snapshot
8.7.3.Operating business segments
8.7.4.Product portfolio
8.8.PFIZER INC.
8.8.1.Company overview
8.8.2.Company snapshot
8.8.3.Operating business segments
8.8.4.Product portfolio
8.8.5.Business performance
8.9.Shire Plc.
8.9.1.Company overview
8.9.2.Company snapshot
8.9.3.Operating business segments
8.9.4.Product portfolio
8.10.Teva Pharmaceuticals, Inc.
8.10.1.Company overview
8.10.2.Company snapshot
8.10.3.Operating business segments
8.10.4.Product portfolio
8.10.5.Business performance
8.10.6.Key strategic moves and developments
LIST OF TABLES
TABLE 01.GLOBAL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 02.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR NUEROVASCULAR DISEASE, BY REGION, 2020–2030 ($MILLION)
TABLE 03.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR DEGENERATIVE DISEASE, BY TYPE, 2020–2030 ($MILLION)
TABLE 04.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR DEGENRATIVE DISEASE, BY REGION, 2020–2030 ($MILLION)
TABLE 05.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR MENTAL HEALTH, BY TYPE, 2020–2030 ($MILLION)
TABLE 06.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR MENTAL HEALTH MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 07.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR INFECTIOUS DISEASE, BY REGION, 2020–2030 ($MILLION)
TABLE 08.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET OTHERS FOR MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 09.GLOBAL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 10.HOSPITAL-BASED PHARMACIES MARKET, BY REGION, 2020–2030 ($MILLION)
TABLE 11.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY REGION, 2020–2030 ($MILLION)
TABLE 12.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR ONLINE PHARMACY, BY REGION, 2020–2030 ($MILLION)
TABLE 13.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020-2030 ($MILLION)
TABLE 14.CENTRAL NERVOUS DISORDERS THERAPEUTICS FOR PEDIARTIC, BY REGION, 2020-2030 ($MILLION)
TABLE 15.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR ADULTS, BY REGION, 2020-2030 ($MILLION)
TABLE 16.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR GERIARTIC, BY REGION, 2020-2030 ($MILLION)
TABLE 17.GLOBAL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKEGLOBAL, BY REGION, 2020–2030 ($MILLION)
TABLE 18.NORTH AMERICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 19.U.S. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 20.U.S. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 21.U.S. CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 22.CANADA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 23.CANADA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 24.MEXICO CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 25.MEXICO CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 26.MEXICO CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 27.NORTH AMERICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 28.NORTH AMERICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 29.NORTH AMERICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 30.EUROPE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 31.GERMANY CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 32.GERMANY CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 33.GERMANY CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 34.FRANCE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 35.FRANCE L CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 36.FRANCE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 37.UK CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 38.UK CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 39.UK CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 40.ITALY CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 41.ITALY CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 42.ITALY L CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 43.SPAIN CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 44.SPAIN CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 45.SPAIN CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 46.REST OF EUROPE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 47.REST OF EUROPE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 48.REST OF EUROPE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 49.EUROPE CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 50.EUROPE L CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 51.EUROPE G CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 52.ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 53.JAPAN CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 54.JAPAN CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 55.JAPAN CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET , BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 56.CHINA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET , BY DISEASE, 2020–2030 ($MILLION)
TABLE 57.CHINA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET , BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 58.CHINA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET , BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 59.AUSTRALIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 60.AUSTRALIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 61.AUSTRALIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 62.INDIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 63.INDIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 64.INDIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 65.SOUTH KOREA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 66.SOUTH KOREA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 67.SOUTH KOREA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 68.REST OF ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 69.REST OF ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 70.REST OF ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 71.ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 72.ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 73.ASIA-PACIFIC CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 74.LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY COUNTRY, 2020–2030 ($MILLION)
TABLE 75.BRAZIL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 76.BRAZIL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 77.BRAZIL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 78.SAUDI ARABIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 79.SAUDI ARABIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 80.SAUDI ARABIA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 81.SOUTH AFRICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 82.SOUTH AFRICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 83.SOUTH AFRICA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 84.REST OF LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 85.REST OF LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 86.REST OF LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 87.LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISEASE, 2020–2030 ($MILLION)
TABLE 88.LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY DISTRIBUTION CHANNEL, 2020–2030 ($MILLION)
TABLE 89.LAMEA CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET, BY AGE GROUP, 2020–2030 ($MILLION)
TABLE 90.ASTRAZENECA: COMPANY SNAPSHOT
TABLE 91.ASTRAZENECA: OPERATING SEGMENTS
TABLE 92.ASTRAZENECA: PRODUCT PORTFOLIO
TABLE 93.BIOGEN: COMPANY SNAPSHOT
TABLE 94.BIOGEN: OPERATING SEGMENTS
TABLE 95.BIOGEN: PRODUCT PORTFOLIO
TABLE 96.ELI LILLY: COMPANY SNAPSHOT
TABLE 97.ELI LILLY: OPERATING SEGMENTS
TABLE 98.ELLI-LILLY: PRODUCT PORTFOLIO
TABLE 99.J&J: COMPANY SNAPSHOT
TABLE 100.J&J: OPERATING SEGMENTS
TABLE 101.J&J: PRODUCT PORTFOLIO
TABLE 102.MERCK.: COMPANY SNAPSHOT
TABLE 103.MERCK.: OPERATING SEGMENTS
TABLE 104.MERCK & CO.: PRODUCT PORTFOLIO
TABLE 105.NOVARTIS: COMPANY SNAPSHOT
TABLE 106.NOVARTIS: OPERATING SEGMENTS
TABLE 107.NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 108.OSTUKA: COMPANY SNAPSHOT
TABLE 109.OSTUKA PHARMACEUTICALS LTD.: OPERATING SEGMENTS
TABLE 110.OSTUK PHARMACEUTICALS LTD.: PRODUCT PORTFOLIO
TABLE 111.PFIZER: COMPANY SNAPSHOT
TABLE 112.PFIZER: OPERATING SEGMENTS
TABLE 113.PFIZER: PRODUCT PORTFOLIO
TABLE 114.SHIRE: COMPANY SNAPSHOT
TABLE 115.SHIRE: OPERATING SEGMENTS
TABLE 116.SHIRE: PRODUCT PORTFOLIO
TABLE 117.TEVA: COMPANY SNAPSHOT
TABLE 118.TEVA: OPERATING SEGMENTS
TABLE 119.TEVA PHARMACEUTICALS: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01.GLOBAL CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET: SEGMENTATION
FIGURE 02.TOP INVESTMENT POCKETS
FIGURE 03.TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION, 2021–2030
FIGURE 04.TOP WINNING STRATEGIES:BY DEVELOPMENT, 2021–2030
FIGURE 05.TOP WINNING STRATEGIES: BY COMPANY, 2021-2030 (%)
FIGURE 06.TOP POSITIONING PLYAERS, 2021-2030
FIGURE 08.MODERATE BARGAINING POWER OF BUYERS
FIGURE 09.MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 10.MODERATE THREAT OF SUBSTITUTION
FIGURE 11.MODRATE THREAT OF NEW ENTRANT
FIGURE 12.HIGH COMPETITIVE RIVALRY
FIGURE 13.MARKET DYNAMICS
FIGURE 14.COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR NUEROVASCUALR DISEASE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 15.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR ALZHEIMER'S DISEASE MARKET, 2020–2030 ($MILLION)
FIGURE 16.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR PARKINSON’S DISEASE, 2020–2030 ($MILLION)
FIGURE 17.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR MULTIPLE SCLEROSIS, 2020–2030 ($MILLION)
FIGURE 18.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR OTHERS, 2020–2030 ($MILLION)
FIGURE 19.COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR DEGENRATIVE DISEASE, BY COUNTRY, 2020 & 2030 (%)
FIGURE 20.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR PSYCOTIC DISORDER, 2020–2030 ($MILLION)
FIGURE 21.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR ANXIETY, 2020–2030 ($MILLION)
FIGURE 22.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR DEPRESSION, 2020–2030 ($MILLION)
FIGURE 23.CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR OTHERS, 2020–2030 ($MILLION)
FIGURE 24.COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR MENTAL HEALTH, BY COUNTRY, 2020 & 2030 (%)
FIGURE 25.COMPARATIVE ANALYSIS OF I CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR INFECTIOUS DISEASE, MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 26.COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR OTHERS MARKET, BY COUNTRY, 2020 & 2030 (%)
FIGURE 27.COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKETFOR HOSPITAL-BASED PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 28.COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR RETAIL PHARMACIES, BY COUNTRY, 2020 & 2030 (%)
FIGURE 29.COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKETFOR ONLINE PHARMACY, BY COUNTRY, 2020 & 2030 (%)
FIGURE 30.COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKETFOR PEDIARTIC (POCT), BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 31.COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS MARKET FOR ADULT, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 32.COMPARATIVE ANALYSIS OF CENTRAL NERVOUS DISORDERS THERAPEUTICS GERIARTIC, BY COUNTRY, 2020 & 2030 ($MILLION)
FIGURE 33.ASTRAZENECA: NET SALES, 2018–2020 ($MILLION)
FIGURE 34.ASTRAZENECA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 35.ASTRAZENECA: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 36.BIOGEN: NET SALES, 2018–2020 ($MILLION)
FIGURE 37.BIOGEN REVENUE SHARE BY REGIONT, 2020 (%)
FIGURE 38.NET SALES, 2018–2020 ($MILLION)
FIGURE 39.ELI LILLY REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 40.ELI LILLY: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 41.NET SALES, 2018–2020 ($MILLION)
FIGURE 42.J&J: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 43.J&J: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 44.NET SALES, 2018–2020 ($MILLION)
FIGURE 45.MERCK: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 46.MERCK: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 47.NOVARTIS: NET SALES, 2018–2020 ($MILLION)
FIGURE 48.NOVARTIS: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 49.NOVARTIS: REVENUE SHARE BY REGION, 2020 (%)
FIGURE 50.PFIZER NET SALES, 2019–2020 ($MILLION)
FIGURE 51.PFIZER: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 52.PFIZER: REVENUE SHARE BY GEOGRAPHY, 2018 (%)
FIGURE 53.TEVA: NET SALES, 2018–2020 ($MILLION)
FIGURE 54.TEVA: REVENUE SHARE BY SEGMENT, 2020 (%)
FIGURE 55.TEVA: REVENUE SHARE BY REGION, 2020 (%)
This section provides opinions of the top-level CXOs in the central nervous system disorder treatment industry. According to the CXOs, central nervous system disorder that affects the structure and function of the brain and spinal cord and cause diseases and disturbs mental health in population of all age group, mostly in geriatric population. Diseases such as neurodegenerative diseases, degenerative diseases, Alzheimer’s disease, Parkinson's disease, multiple sclerosis, autoimmune & inflammatory diseases, genetic disorders, tumors, and cancers are disorders of central nervous system that boost the market growth. The degenerative disease segment dominated in 2020, and is expected to remain dominant throughout the forecast period.
According to CXOs, the central nervous system disorder treatment market is anticipated to witness considerable growth in the future, owing to rise in awareness regarding neurovascular diseases, degenerative diseases, infectious diseases, and mental health by government and non-government organizations and surge in prevalence of lifestyle-associated CNS disorders boost growth of the central nervous system disorder treatment market. Moreover, key pharmaceutical players are focusing on new therapies to prevent or improve symptoms of neurological disorders and various other key players in the central nervous system disorder treatment market are heavily investing and launching novel drugs, which is anticipated to boost the market for central nervous system during the forecast period.
CXOs further stated that growth in geriatric population and increase in disorders in emerging countries such as some part of Asia, owing to less neurologic training centres and availability of laboratory facilities and equipment that limited in emerging countries are expected to present lucrative opportunities for the market expansion.
A. The total market value of central nervous system disorders treatment market is $1,17,556.10 million in 2020
A. The forecast period in the report is from 2021 to 2030
A. The market value of central nervous system disorders treatment Market in 2020 was $1,17,556.10 Million
A. The base year for the report is 2020
A. Yes, central nervous system disorders treatment companies are profiled in the report
A. The top companies that hold the market share in central nervous system disorders treatment Market are Biogen, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Company, Merck & Co.. Astra Zeneca, Shire PLC, Novartis AG, Teva Pharmaceutical Industries Ltd., Johnson & Johnson Services, Inc. and Pfizer, Inc.
A. The key trends in the central nervous system disorders treatment Market are increasing prevalence of CNS disorders and presence of strong pipeline drugs are the major factors that drive the growth of the central nervous system disorder treatment market .
Start reading instantly.
This Report and over 66,804+ more Reports, Available with Avenue Library. T&C*.
Enterprise
License/PDF
Library
Membership
*Taxes/Fees, if applicable will be added during checkout. All prices in USD
To ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Get insights on topics that are crucial for your business. Stay abreast of your interest areas.
Get Industry Data AlertsTo ensure high-level data integrity, accurate analysis, and impeccable forecasts
For complete satisfaction
On-demand customization of scope of the report to exactly meet your needs
Targeted market view to provide pertinent information and save time of readers
Contact Details
Need to talk to an expert? Book your free consultation and let our research experts help you with your needs/problems.
Global Report 
Regional Report
Country Report
Related Report